{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:16:47Z","timestamp":1789161407116,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clim.2020.108541","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T04:16:38Z","timestamp":1594786598000},"page":"108541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease"],"prefix":"10.1016","volume":"219","author":[{"given":"Ankit K.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2020.108541_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.clim.2020.108541_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.clim.2020.108541_bb0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.clim.2020.108541_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"16","key":"10.1016\/j.clim.2020.108541_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.clim.2020.108541_bb0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.clim.2020.108541_bb0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.clim.2020.108541_bb0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2020.108541_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2020.108541_bb0050","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A theoretical model of gamma-globulin catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.clim.2020.108541_bb0055","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/ajt.13902","article-title":"Inflammation causes resistance to anti-CD20-mediated B cell depletion","volume":"16","author":"Laws","year":"2016","journal-title":"Am. J. Transplant."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:02:42Z","timestamp":1761494562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620301169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":11,"alternative-id":["S1521661620301169"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108541","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108541"}}